Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity.Īfter completion of study treatment, patients are followed up at 30 days, then every 6 months for 10 years. Treatment repeats every 21 days for up to 14 cycles in the absence of disease progression or unacceptable toxicity.ĪRM II: Patients receive T-DM1 IV over 30-90 minutes on day 1 and tucatinib PO BID on days 1-21.
OUTLINE: Patients are randomized to 1 of 2 arms.ĪRM I: Patients receive T-DM1 intravenously (IV) over 30-90 minutes on day 1 and placebo orally (PO) twice daily (BID) on days 1-21. To evaluate whether treatment with tucatinib plus T-DM1 compared to treatment with T-DM1 alone (T-DM1 plus placebo) reduces the incidence of brain metastases.
To evaluate whether treatment with tucatinib plus T-DM1 compared to treatment with T-DM1 alone (T-DM1 plus placebo) improves the following: To determine if the invasive disease-free survival (iDFS) with T-DM1 and tucatinib is superior to the iDFS in the control arm (T-DM1 + placebo) when administered to high risk patients with HER2-positive breast cancer and residual disease after neoadjuvant HER2-directed therapy. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. “Asian Plaything and the Traditional western Look: Notes on the Feminine Dollification in Southerly Korea,” Oriental Women27.2 (2011): 81-111.This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. The Asia Pacific Journal of Anthropology. 'Korean Cuties: Understanding Performed Winsomeness (Aegyo) in Southerly Korea'. Singing Music and Modern Identities: Limitless Voices in East Asian countries and the Western world. Korean Masculinities and Transcultural Usage: Yonsama, Rain, Oldboy, K-Pop Idols. Using cute hand gestures and expressions in photos, for instance, are frequently seen habits in numerous young females in Sth Korea. Puzar argues that aegyoin well-known culture impacts how youthful South Korean women act, specifically in intimate relationships.
0 kommentar(er)
